Cytokine/chemokine dysregulation in progressive MS patient is apparent and can be modulated by calpain inhibition.
Cytokine/chemokine dysregulation in progressive MS patient is apparent and can be modulated by calpain inhibition.
复制标题
DOI：
10.1007/s11011-019-00521-1
复制
发表时间：
2020-02
影响因子：
3.6
通讯作者：
中科院分区：
文献类型：
--
作者：
这项研究考察了一位62岁的非洲裔美国男性进行性多发性硬化症(MS)患者的细胞因子/趋化因子特征。多发性硬化症患者的MRI图像显示广泛的白质受累，在脑室周围区域有多个病变。来自两次不同临床就诊的患者血浆和外周血单个核细胞(PBMC)上清液或PBMC衍生T细胞上清液的42-plex Discovery Assay®(EVE Technologies)检测显示，细胞因子/趋化因子水平存在巨大差异。此外，某些细胞因子/趋化因子在体外与较大的患者组或使用钙蛋白酶抑制剂治疗的患者的PBMC相比有显著差异。有趣的是，MS PBMCs中的大量细胞因子/趋化因子和生长因子受到Calain抑制的调节，这表明这些发现对于设计更好的治疗进行性MS的方法具有临床意义。
This study examines the cytokine/chemokine profile of a 62-year-old African American male with progressive multiple sclerosis (MS). MRI images of the MS patient demonstrated generalized white matter involvement with multiple lesions in the periventricular area. A 42-plex Discovery Assay® (Eve Technologies) of the patient’s plasma and peripheral blood mononuclear cells (PBMCs) supernatant or PBMC-derived T cell supernatant samples from two separate clinic visits revealed vastly differing cytokine/chemokine levels. In addition, certain cytokine/chemokine profiles had notable differences when compared to the larger patient group or patients’ PBMCs treated with a calpain inhibitor in vitro. Interestingly, large numbers of cytokines/chemokines and growth factors in MS PBMCs are modulated by calpain inhibition, suggesting the clinical significance of these findings in designing better therapeutics against progressive MS.
影响因子：
4.7
作者：
Guyton MK;Brahmachari S;Das A;Samantaray S;Inoue J;Azuma M;Ray SK;Banik NL
通讯作者：
Banik NL